Timothy Barberich
Chairman at TSCAN THERAPEUTICS, INC.
Net worth: 796 271 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alexey V. Eliseev | M | - |
MirImmune, Inc.
 MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA.
Bionevia Pharmaceuticals, Inc.
 Bionevia Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Bionevia Pharmaceuticals, Inc. operates as a chronic disease hospital. Timothy Joseph Barberich has been the CEO of the American company since 2008. | 9 years |
| Gavin MacBeath | M | 54 | 6 years | |
| Joseph Virgilio | M | - | 4 years | |
| Alexey Wolfson | M | - |
MirImmune, Inc.
MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA. | 9 years |
| Daniel Calkins | M | 37 | 6 years | |
| Brian Stuglik | M | 64 | 7 years | |
| Leiden Dworak | M | - | 2 years | |
| Gabriela Gruia | M | 67 | 3 years | |
| Stephen Linhares | M | 67 | 5 years | |
| Michelle Robertson | F | 57 | 3 years | |
| Zoran Zdraveski | M | 54 | 3 years | |
| R. Woods | M | 57 | 1 years | |
| Mark David Lerdal | M | 65 | 4 years | |
| Eric Rowinsky | M | 67 | 7 years | |
| Katina Dorton | F | 66 | 3 years | |
| Barbara Klencke | M | 66 | 1 years | |
| Paul Bunn | M | 79 | 3 years | |
| Stephen Biggar | M | 53 | 3 years | |
| John Johnson | M | 66 | 4 years | |
| Janell Shields | F | - | 8 years | |
| Ann Hargraves | F | - | 4 years | |
| Jason Amello | M | 55 | - | |
| Ginger Glaser | F | - | 4 years | |
| Heather Savelle | F | - | 3 years | |
| Shrikanta Chattopadhya | M | - | - | |
| Ray Lockard | M | - | 1 years | |
| Justin McCue | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Solomon | M | - | - | |
| Anthony A. McKinney | M | 62 |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | 6 years |
| Robert M. Forrester | M | 60 | 8 years | |
| Christoph H. Westphal | M | 56 | 3 years | |
| David McIntyre | M | 53 | 6 years | |
| Ittai Harel | M | 56 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 11 years |
| Robert Crane | M | 65 | 11 years | |
| Adrian Adams | M | 73 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 4 years |
| David Southwell | M | 63 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 20 years |
| Antony Loebel | M | 64 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | - |
| Michael D. Dale | M | 64 | 2 years | |
| James Murphy | M | 67 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 6 years |
| Brian Silver | M | 55 | 2 years | |
| Joseph Chiapponi | M | 55 | 6 years | |
| Lea Hachigian | M | - | 3 years | |
| Mark Iwicki | M | 57 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 5 years |
| Jodie Morrison | F | 48 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 11 years |
| Argeris Karabelas | M | 71 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 years |
| Philip Vickers | M | 64 |
Resolvyx Pharmaceuticals, Inc.
 Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | 2 years |
| Robert Thomas | M | 79 | 8 years | |
| Donald R. Kiepert | M | 76 |
Point Therapeutics, Inc.
 Point Therapeutics, Inc. BiotechnologyHealth Technology Point Therapeutics, Inc. develops drugs for the treatment of cancer and blood cell disorders. The company's PT-100 (talabostat) treats anemia and neutropenia (low levels of white blood cells), which can be caused by diseases or medical treatments, such as chemotherapy. The drugs stimulate production of proteins that build up the body's immune system against malignant tumors. Point Therapeutics, Inc. is located in Boston, MA. | 14 years |
| C. Larkin | M | 75 | 8 years | |
| Peter F. McAree | M | 59 | - | |
| Jim O'Shea | M | 74 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 8 years |
| Richard H. Aldrich | M | 69 | 4 years | |
| Dave Bruce | M | 46 | 2 years | |
| Charles Carter | M | 57 | 5 years | |
| Daniel Moore | M | 63 | 6 years | |
| Lauren Farrell | F | 56 | 7 years | |
| Houry Youssoufian | F | - | - | |
| Stuart Randle | M | 64 | 11 years | |
| Juliet Thompson | F | 57 | 3 years | |
| Nandita Shangari | M | 43 | - | |
| Campbell Murray | M | 48 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 5 years |
| Christopher J. M. Taylor | M | - | 7 years | |
| Jessica Fees | F | 52 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 6 years |
| David A. Kessler | M | 72 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | - |
| Lesley Solomon | F | 52 | 2 years | |
| Andrew Levine | M | - | 11 years | |
| Andrew Hedin | M | 39 | - | |
| Brian Callahan | M | - | 2 years | |
| Isai Peimer | M | 46 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 years |
| Brian Sullivan | M | - | 9 years | |
| Stephen Buckley | M | 74 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | - |
| Stephen Sherwin | M | 75 | 3 years | |
| Scott Schorer | M | 55 | 4 years | |
| Alison Lawton | F | 62 | 8 years | |
| Gina Consylman | F | 52 | 3 years | |
| Carsten Boess | M | 57 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| J. Carroll | M | 74 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 2 years |
| Clarence Machado | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 2 years |
| Oern Stuge | M | 70 | 3 years | |
| Bruce Wendel | M | 70 | 5 years | |
| Franklin P. Bymaster | M | 78 |
Neurovance, Inc.
Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | - |
| Robert Bernard Stockman | M | 71 | 8 years | |
| S. Phanstiel | F | 65 | 6 years | |
| Robert E. Yocher | M | 73 | 4 years | |
| Cheryl L. Cohen | F | 58 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 5 years |
| Paul D. Rubin | M | 70 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.
Resolvyx Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | 9 years |
| Christine Bennett | M | 68 | 4 years | |
| Cynthia Feldmann | F | 71 | 4 years | |
| Martin Vogelbaum | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 years |
| Anne Jillian Keating | F | 70 | 6 years | |
| Graham Bradley | M | 75 | 6 years | |
| Paul Friedman | M | 81 | 3 years | |
| Martin D. Williams | M | 58 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 2 years |
| Louis Vaickus | M | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 4 years |
| Denis N. Wade | M | 86 | 8 years | |
| Susan Stewart | F | 64 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 6 years |
| Lawrence Knopf | M | 62 | 5 years | |
| John S. McBride | M | 72 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | 3 years |
| Madelyn Zeylikman | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Timothy Barberich
- Personal Network